Entrada Therapeutics Inc (TRDA) Price & Analysis

Compare

147 Followers

TRDA Stock Chart & Stats

$10.82

-$0.56(-3.25%)

At close: Jan 08 4:00 PM EST

$10.82

-$0.56(-3.25%)

Day’s Range― - ―

52-Week Range$4.93 - $14.02

Previous CloseN/A

Volume35.15K

Average Volume (3M)208.91K

Market Cap

$413.53M

Enterprise Value$343.98M

Total Cash (Recent Filing)$326.84M

Total Debt (Recent Filing)$52.40M

Price to Earnings (P/E)―

Beta1.53

Next Earnings

Mar 18, 2026

EPS Estimate

-1.17

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.06

Shares Outstanding38,219,230

10 Day Avg. Volume271,941

30 Day Avg. Volume208,908

Financial Highlights & Ratios

PEG Ratio-0.01

Price to Book (P/B)1.50

Price to Sales (P/S)3.06

P/FCF Ratio-14.43

Enterprise Value/Market Cap0.83

Enterprise Value/Revenue5.59

Enterprise Value/Gross Profit14.85

Enterprise Value/Ebitda-3.02

Forecast

1Y Price Target

$18.00

Price Target Upside66.36% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical MilestonesAnalysts point to multiple Duchenne muscular dystrophy programs progressing toward initial in‑patient clinical readouts in 2026, and positive efficacy signals could materially lift the stock by demonstrating therapeutic benefit.

Pipeline Expansion Into OphthalmologyAdvancement of ocular programs toward a first clinical candidate expected in 2026 broadens the company's addressable markets beyond neuromuscular diseases and may attract new partnerships or investor interest.

Platform ValidationAnalysts expect that successful results from candidates using the company's endosomal escape vehicle delivery platform would validate its differentiated efficacy and safety profile, boosting confidence across the pipeline.

Bears Say

Entrada Therapeutics Inc News

Entrada Therapeutics initiated with an Outperform at Oppenheimer

Oppenheimer analyst Kostas Biliouris initiated coverage of Entrada Therapeutics (TRDA) with an Outperform rating and $21 price target...

9d ago

TRDA

Entrada Therapeutics reports progress across development portfolio

Entrada Therapeutics (TRDA) reported progress across its robust development portfolio of RNA-based programs for the potential treatment of...

29d ago

TRDA

Entrada Therapeutics: Advancing DMD and DM1 Pipeline with Emerging Ophthalmology Assets Supports Buy Rating and $20 Target

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Entrada Therapeutics Inc. The associated price...

25d ago

TRDA

Entrada Therapeutics highlights RNA pipeline progress and outlook

Entrada Therapeutics Inc ( ($TRDA) ) has provided an update. On January 8, 2026, Entrada Therapeutics reported significant...

29d ago

TRDA

Entrada Therapeutics Reports Increased Losses Amid R&D Expansion

Entrada Therapeutics Inc ( ($TRDA) ) has released its Q3 earnings. Here is a breakdown of the information...

3M ago

TRDA

Entrada Therapeutics price target lowered to $13 from $17 at Roth Capital

Roth Capital lowered the firm’s price target on Entrada Therapeutics (TRDA) to $13 from $17 and keeps a...

3M ago

TRDA

Promising Outlook for Entrada Therapeutics: Strategic Advancements in DMD and DM1 with Novel EEV Platform

William Blair analyst Myles Minter has reiterated their bullish stance on TRDA stock, giving a Buy rating today....

3M ago

TRDA

Promising Advancements and Strategic Positioning Drive Buy Rating for Entrada Therapeutics Inc.

TD Cowen analyst Joseph Thome has maintained their bullish stance on TRDA stock, giving a Buy rating on...

3M ago

TRDA

Entrada Therapeutics files $400M mixed securities shelf

07:49 EST Entrada Therapeutics (TRDA) files $400M mixed securities shelf Published first on TheFly – the ultimate source...

3M ago

TRDA

Entrada Therapeutics reports Q3 EPS ($1.06), consensus (96c)

Reports Q3 revenue $1.614M, consensus $8.62M. “This year, we have strategically positioned Entrada to significantly advance what we...

3M ago

TRDA

Entrada Therapeutics: Undervalued Leader in RNA Therapeutics with Promising DMD Pipeline

Entrada Therapeutics Inc, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju...

3M ago

TRDA

3 Best Stocks to Buy Now, 10/24/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

3M ago

EXOD

NRIX

Entrada Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

Goldman Sachs analyst Paul Choi initiated coverage of Entrada Therapeutics (TRDA) with an Early-Stage Biotech designation, saying the...

5M ago

TRDA

Entrada Therapeutics price target lowered to $17 from $21 at Roth Capital

Roth Capital lowered the firm’s price target on Entrada Therapeutics (TRDA) to $17 from $21 and keeps a...

6M ago

TRDA

TRDA FAQ

What was Entrada Therapeutics Inc’s price range in the past 12 months?

Entrada Therapeutics Inc lowest stock price was $4.93 and its highest was $14.02 in the past 12 months.

What is Entrada Therapeutics Inc’s market cap?

Entrada Therapeutics Inc’s market cap is $413.53M.

When is Entrada Therapeutics Inc’s upcoming earnings report date?

Entrada Therapeutics Inc’s upcoming earnings report date is Mar 18, 2026 which is in 40 days.

How were Entrada Therapeutics Inc’s earnings last quarter?

Entrada Therapeutics Inc released its earnings results on Nov 06, 2025. The company reported -$1.06 earnings per share for the quarter, missing the consensus estimate of -$0.94 by -$0.12.

Is Entrada Therapeutics Inc overvalued?

According to Wall Street analysts Entrada Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Entrada Therapeutics Inc pay dividends?

Entrada Therapeutics Inc does not currently pay dividends.

What is Entrada Therapeutics Inc’s EPS estimate?

Entrada Therapeutics Inc’s EPS estimate is -1.17.

How many shares outstanding does Entrada Therapeutics Inc have?

Entrada Therapeutics Inc has 38,219,230 shares outstanding.

What happened to Entrada Therapeutics Inc’s price movement after its last earnings report?

Entrada Therapeutics Inc reported an EPS of -$1.06 in its last earnings report, missing expectations of -$0.94. Following the earnings report the stock price went up 0.144%.

Which hedge fund is a major shareholder of Entrada Therapeutics Inc?

Currently, no hedge funds are holding shares in TRDA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Entrada Therapeutics Inc Stock Smart Score

Neutral

Fundamentals

Return on Equity

-27.11%

Trailing 12-Months

Asset Growth

-25.55%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Entrada Therapeutics Inc

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Entrada Therapeutics Inc (TRDA) Earnings & Revenues

Historic Earnings Reports

TRDA Stock 12 Month Forecast

Average Price Target

$18.00

▲(66.36% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","13":"$13","22":"$22","8.5":"$8.5","17.5":"$17.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$21.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,8.5,13,17.5,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.85,12.553846153846154,13.257692307692308,13.961538461538462,14.665384615384616,15.36923076923077,16.073076923076922,16.776923076923076,17.48076923076923,18.184615384615384,18.888461538461538,19.592307692307692,20.296153846153846,{"y":21,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.85,12.323076923076922,12.796153846153846,13.269230769230768,13.742307692307692,14.215384615384615,14.688461538461539,15.161538461538461,15.634615384615385,16.107692307692307,16.58076923076923,17.053846153846152,17.526923076923076,{"y":18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.85,11.938461538461539,12.026923076923076,12.115384615384615,12.203846153846154,12.292307692307691,12.38076923076923,12.46923076923077,12.557692307692308,12.646153846153846,12.734615384615385,12.823076923076924,12.911538461538461,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.29,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.44,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.94,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.11,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.38,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.88,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.95,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.28,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.85,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >